Stay updated on SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.

Latest updates to the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page
- Check6 days agoChange DetectedAdded entries for Results Posted, More Information, Adverse Events, Outcome Measures (Results), Baseline Characteristics, Participant Flow, and Document Section under the Study Record History dated 2025-12-23. Removed the 'Results Submitted' entry dated 2025-12-08.SummaryDifference0.5%

- Check13 days agoChange DetectedRevision: v3.3.3 was added to the page footer, and the HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed. This appears to be a routine maintenance update that does not affect trial details or user actions.SummaryDifference0.1%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedVersion dated 2025-12-08 adds a 'Results Submitted' entry and updates the Study Status; the prior 2025-11-10 entry of 'No Results Posted' was removed.SummaryDifference0.2%

- Check35 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.3.1 was removed from the record history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check42 days agoChange DetectedRevision: v3.3.1 was added and Revision: v3.2.0 was removed from the page header/footer to reflect the latest site revision.SummaryDifference0.0%

- Check49 days agoChange DetectedDifference0.4%

Stay in the know with updates to SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.